Disclosure statement
TM received research funding from MSD, Novartis Pharma, LSI Medience, Medical & Biological Laboratories, and Asahi Kasei Corporation, and personal fees from Pfizer Inc., MSD, Janssen Pharma, Sumitomo Dainippon Pharma, Novartis Pharma, Kyowa Kirin, Chugai Pharmaceutical, Shionogi & Co., Japan Blood Products Organization, Takeda Pharmaceutical, Ono Pharmaceutical, Shire, Eisai, and Astellas Pharma; TK received personal fees from Chugai Pharmaceutical, Eisai, Kyowa Kirin, Janssen Pharma, Takeda Pharmaceutical, and Bristol-Myers Squibb; JK received personal fees from Astellas Pharma, Otsuka Pharmaceutical, Janssen Pharma, Pfizer, Takeda Pharmaceutical, and JCR Pharmaceuticals; TS received personal fees from Janssen Pharma, Kyowa Kirin, Takeda Pharmaceutical, Celgene, Ono Pharmaceutical, and Eisai; SO received research funding from Chugai Pharmaceutical, Sumitomo Dainippon Pharma, Pfizer, Teijin Pharma, Novartis Pharma, Bristol-Myers Squibb, Mochida Pharmaceutical, JCR Pharmaceuticals, Toyama Chemical, Takeda Pharmaceutical, Daiichi Sankyo, Shionogi & Co., Sanofi, Kyowa Kirin, Ono Pharmaceutical, Otsuka Pharmaceutical, Eisai, Asahi Kasei Corporation, and Japan Blood Products Organization, and personal fees from Chugai Pharmaceutical, Eisai, Kyowa Kirin, Janssen Pharma, and Takeda Pharmaceutical.